In November 2003, Biogen Idec Inc. (NASDAQ: BIIB) was formed from the merger of two of the world's leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. This combination has resulted in a fusion of complementary strengths in therapeutic focus, research and development capabilities, manufacturing expertise, global infrastructure and financial position. Biogen Idec intends to continue its growth through discovery, development and commercialization of its own innovative products and through strategic alliances as the partner-of-choice for biologics development, manufacturing and marketing.

Biogen Idec is dedicated to pursuing the creativity of science. The company's products and development programs address a variety of key medical needs in the areas of oncology, neurology, dermatology and immunology. The company is driven by scientific excellence that achieves new standards of care. Biogen Idec invested nearly 30% of 2006 revenues in Research and Development.

In addition to Biogen Idec's promising portfolio of drug candidates, the company's capabilities and capacity for protein manufacturing are world-class in quality and scale. The company is one of a handful of biotechnology companies that has licensed and dedicated biological bulk-manufacturing facilities, which include its large-scale manufacturing plant in Research Triangle Park, North Carolina, one of the world's largest cell culture facilities, and the world-class 90,000 liter facility for the manufacture of biologics in Hillerod, Denmark, currently being constructed.

Biogen Idec is headquartered in Cambridge, MA and maintains its International headquarters in Zug, Switzerland, with additional centers of excellence in San Diego, CA, Hoofddorp, NL and Maidenhead, UK. The company also has offices throughout Europe, in Canada, Australia, Japan, and operates a global distribution network which covers over 70 markets.